Posted inHematology-Oncology news Specialties
Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.